Overview
Cabaletta Bio, Inc. (NASDAQ:CABA) saw its shares climb 12% on Monday after the company priced an underwritten offering of common stock expected to raise approximately $150 million in gross proceeds before fees and expenses. The clinical-stage biotechnology firm set the offering price at $2.90 per share and is selling all of the shares included in the transaction.
Details of the offering
The company priced 51,725,000 shares at $2.90 per share, a level that represents the at-the-market price under Nasdaq rules. For reference, Cabaletta's shares had closed at $2.94 on Friday.
Aggregate gross proceeds from the sale, before deducting underwriting discounts, commissions and offering expenses, are expected to be approximately $150 million. The offering is slated to close on or about May 5, 2026, subject to customary closing conditions.
Investor participation and managers
The offering includes participation from a mix of existing and new institutional investors. Named participants are Bain Capital Life Sciences, Adage Capital Management and Cormorant Asset Management, together with other existing investors, multiple new mutual and sovereign wealth funds, and Eli Lilly and Company.
TD Cowen, Guggenheim Securities and Cantor are acting as joint book-running managers for the offering, while H.C. Wainwright & Co. is serving as lead manager.
Company focus
Cabaletta Bio is a clinical-stage biotechnology company focused on developing targeted cell therapies for patients with autoimmune diseases. The company confirmed it is selling all of the shares in the offering.
Market reaction and context
Following the pricing announcement, Cabaletta's stock appreciated by 12% on Monday. The pricing at $2.90 per share aligns with Nasdaq's at-the-market pricing framework cited by the company, and the offering brings in participation from both long-standing investors and a set of new institutional participants.
As with any equity offering, closing is contingent on customary conditions and is expected to occur on or about May 5, 2026.